Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, announced its financial results for the full year ended December 31, 2025, along with significant corporate updates. The company reported a net loss attributable to common stockholders of $61.8 million for 2025, a notable decrease from a net loss of $138.4 million in 2024. This reduction in losses is attributed to a strategic realignment that focused on core assets and a decrease in research and development expenses, which fell to $62.0 million from $118.1 million in the previous year. The company highlighted its ongoing clinical trials, including two Phase II studies for icovamenib in type 2 diabetes, with primary endpoint data expected by the end of 2026. Additionally, Biomea initiated a Phase I trial for GLP-131, targeting obesity, with initial data anticipated in the second quarter of 2026. The company maintains a cash runway into the first quarter of 2027, which positions it well for upcoming milestones. The leadership expressed optimism about the company's trajectory, emphasizing the importance of the clinical data expected in the near future.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.